Genomic Vision SA
GVI.EU
$0.00
Closing
0.00
1D
0.00
YTD
Market cap
$748494
52 week high
$0.05
52 week low
$0.00
Volume
38,489,238
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$748494
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
0
P/E
Operating Margin
-865.09%
Beta
-0.94
Revenue Growth (Annual)
-8.07%
52 week high
$0.05
52 week low
$0.00
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Genomic Vision SA is a France-based biotechnology company. It develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The Company uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. It develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.
